Alprostadil vs Tadalafil Peptide
A side-by-side research comparison of Alprostadil and Tadalafil Peptide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Alprostadil | Tadalafil Peptide |
|---|---|---|
| Full name | Alprostadil (Prostaglandin E1) | Tadalafil-Peptide Conjugate (Experimental) |
| Category | Sexual Health | Sexual Health |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Alprostadil activates prostaglandin receptors that raise intracellular cAMP in cavernosal smooth muscle, causing vasodilation and increased blood inflow to produce an erection regardless of nerve signaling or arousal. | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. |
| Molecular weight | 354.5 Da | ~2,500 Da (conjugate) |
| Half-life | Very short (minutes, locally metabolized) | 8-12 hours |
| Bioavailability | Intracavernosal injection or intraurethral suppository | Targeted (topical/local) |
| Typical dose | Provider-titrated per response | 1-5 mg equivalent |
| Frequency | As needed before activity | As needed |
| Route | Intracavernosal injection or urethral pellet | Topical or local injection |
Alprostadil reported benefits
- Effective for erectile dysfunction
- Works independent of arousal
- Rapid onset
- Useful when oral PDE5 inhibitors fail
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Related comparisons
Research and educational reference only. Not medical advice.